Taher Sathaliya, PhD
Commercial Drug Development; Biomarkers
Translational scientist with industry experience in the development of cancer immunotherapy and drugs for autoimmune diseases, expertise induce early translational sciences, and clinical biomarker discovery and development. Trained immunologist with a track record of publications in high-impact journals. Contributing member of the JLABS – JPAL program that pairs researchers from Janssen Pharmaceuticals with start-up companies from within the JLABS community of companies. Scientific Advisor to Infixion Bioscience since 2021, with a focus on Biomarker development for the NF1.